Compare Abeona Therapeutics Inc (ABEO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.47 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 111.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| ABEO | TTWO | |
|---|---|---|
Market Cap | $421.19M | $46.84B |
Sector | Health | Media |
52-Week High | $7.45 | $262.29 |
52-Week Low | $4.17 | $189.69 |
Enterprise Value | $276.10M | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Take-Two Interactive (TTWO) trades at $244.33, down 3.64% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by NBA 2K and Grand Theft Auto performance, while the company maintains focus on the upcoming GTA VI launch in November 2026. Fundamentals show revenue growth to $5.63B in 2025, but net losses persist, with a negative net income margin of -4.79%.
The stock's upside potential is tied to GTA VI's success, with a consensus price target of $300.55 offering 23% upside. Key risks include execution on the high-stakes game launch, sustained profitability challenges, and competitive pressures in the gaming industry. Investor sentiment remains optimistic due to the blockbuster title's preorder momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
